Time filter

Source Type

Manchester, United Kingdom

So J.,The Christie NHS Foundation Trust
European Journal of Cancer Care | Year: 2010

There has been a plethora of oral chemotherapeutic agents introduced over recent years. For hospital pharmacies this has meant unprecedented activity. At the same time there is pressure to meet waiting time targets and to improve patient experience. The Cancer Centre had already used homecare services for trastuzumab (Herceptin) so it seemed reasonable to apply this to selected oral agents. A formal tender resulted in a contract award for homecare. The service has been running successfully for 3 years with imatinib in chronic myeloid leukaemia and in gastro-intestinal stromal tumour patients. Patients are informed about the homecare supply service in clinic by the nurse or pharmacist, with most patients opting for the service rather than a wait in pharmacy for their prescription. The drug is then delivered by post to the patient's home. We plan to extend the service in the coming months to include a second oral agent, erlotinib for the treatment of non small cell lung cancer. As well as avoiding a patient wait in pharmacy, provision through a homecare company offers a more cost effective way for the Trust to deliver an oral chemotherapy service. By reducing the number of patients arriving in pharmacy for prescriptions, it facilitates the achievement of outpatient waiting time targets and improves the overall patient experience. © 2010 The Author. Journal compilation © 2010 Blackwell Publishing Ltd.

The Christie Nhs Foundation Trust | Date: 2012-06-21

The present invention relates to a phantom for use in the auditing or verification of a proposed radiation therapy regime for administration to a patient. The phantom comprises a housing which is shaped to simulate the anatomical shape of a human head and neck; and a radiation detector module configured to receive at least one radiation detector. The housing defines a cavity in which the radiation detector module can be removeably received such that the radiation detector module occupies a predetermined location within the simulated head and neck of the housing. Said predetermined location encompasses areas of the housing which simulate a target site to which it is proposed to administer radiation to the patient and a location of at least one organ that is susceptible to harm by administration of said radiation.

Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2010.2.4.1-9 | Award Amount: 7.93M | Year: 2011

Loco-regional treatment is the mainstay of cancer cures in non small lung and head and neck cancer. For advanced stage cancer, dose intense multimodality treatment is required yet affected by substantial side effects. Our aim is to improve treatment outcome in locally advanced head and neck and lung cancer patients by: 1. Optimizing local control by introducing novel radiation techniques resulting in redistribution of the radiation dose, creating inhomogeneous dose distribution towards the most active part of the tumour instead of conventional homogenous doses. This redistribution can be performed without increase of toxicity. As recently reported radiation accidents in the US demonstrate, QA is of outmost importance for safe radiation delivery in complex treatments. To assure accurate delivery over time, we will monitor both the patients geometry as well as the delivered dose using image guided adaptive plan modifications and 3D in-vivo dosimetric verification. 2. Maximizing the benefit of combined modality treatment Both cisplatin and Cetuximab in combination with radiotherapy have shown to improve local control and survival but both drugs have severe side effects. As these drugs are not active in all patients, there is a large need to select patients which are sensitive to either drug. For this purpose the uptake of Cetuximab will be estimated by imaging tumour uptake with Zr89 labelled Cetuximab, while cisplatin sensitive tumours can be selected by biomarkers. This proposal will: 1 optimise efficiency by selecting patients on treatment specific tumour response predictors and tailoring radiation to most active parts of the tumour. 2 improve quality of life by withholding ineffective, toxic treatments and redistribution of dose. 3 decrease community costs by reserving expensive treatments for those who will benefit. This will be studied in randomized phase II clinical trials in top European institutes, followed by phase III trials outside this proposal.

Agency: Cordis | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-ITN-2008 | Award Amount: 2.84M | Year: 2009

Considerable resources are devoted to fighting cancer throughout Europe, yet these efforts are not producing the results that health practitioners and citizens might expect. This is partly due to the fragmentation and duplication of research efforts within Member states and the lack of co-ordination at European level. However it can also be attributed to the need to retain and most importantly develop researchers within the EU who have the research skills required to make a real contribution to cancer treatment. The need for quality researchers is particularly acute within the emerging interdisciplinary field of Adoptive Cell Therapy. This promising advance in cancer treatment is based on the exploitation of tumour immunology and genetic technology and built on the specific ideas and techniques originally proposed by the European and Israeli scientists who are members of the ATTRACT network. To facilitate further development within the field of adoptive cell therapy, it is crucial that a co-ordinated and intersectoral approach (combining both the research community and industry) is taken, an approach that broadens the portfolio of skills currently retained within the EU research community. Through the integration Europes undisputed leaders in the field of adoptive cell therapy established in the 2005 FP6 ATTACK project, the ATTRACT network aims to foster the development of a pool of ESRs and ERs by equipping them with the multidisciplinary and complementary skills needed to not only initiate further advances in the field but to become future leaders within the field of adoptive cell therapy for cancer treatment. Such skills are global in demand making each researcher a highly desirable candidate for employment and very mobile across the different career domains.

Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2012.1.4-4 | Award Amount: 8.26M | Year: 2012

The aim of this research is to exploit technology for nucleic acid delivery through the clinical testing of adoptive engineered T cells to treat cancer. Recent innovative developments in cancer gene-immunotherapy have led to very encouraging early clinical results. However, the use of engineered T cells is a challenging and complex field with further development and more proof-of-principle trials needed. This proposal builds upon previous EU funded pre-clinical projects and comprises a multidisciplinary and translational research group with wide-ranging relevant expertise. Building on encouraging clinical results targeting NY-ESO-1 in melanoma and the availability of clinical grade vector, the consortium proposes to rapidly initiate two landmark studies in this field: the first to examine the activity of engineered T cells in oesophago-gastric cancer as an example of a hard to treat common epithelial cancer; the second to undertake a randomised phase II study to determine whether an optimised cell production system developed by the partners improves the current clinical response rates in patients with metastatic melanoma treated with NY-ESO-1 targeted T-cells. Success in these trials will enable the consortia and others to carryout larger trials and potentially approval of this type of therapy as a treatment for multiple cancer types. The inclusion of a major industrial partner focused on cell therapy technology and two SMEs focus on the delivery of cell therapy will facilitate future development of this area following these trials; indeed the project also includes plans to further automate and streamline cell processing to facilitate this development. This project would enhance European expertise and competitiveness in an important emerging market. The research will also support the European biotechnology industry which will be important for the exploitation of these therapies and the successful outcome of this project.

Discover hidden collaborations